ALS, Denali

Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial
The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
ALS drugs from Denali, Calico come up short, marking more failures for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.
Denali Suffers Another ALS Fail With Phase II/III Flop
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and Amylyx have seen similarly disappointing results.
Denali Therapeutics Says ALS Trial Didn't Meet Endpoints
Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.
Denali Therapeutics' ALS drug fails in mid-to-late stage trial
Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
Denali Therapeutics announces HEALEY ALS trial regimen misses endpoints
Denali Therapeutics (DNLI) announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform trial is evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis (ALS).
ALS drug fails stage 3 trial
Secondary endpoints, including the revised ALS functioning rating scale, respiratory function and health-related quality of life also showed no statistically significant improvement compared to the placebo.
GMC Celebrates 25 Years Of The Denali
To commemorate the 25th anniversary of Denali, GMC is offering customers a special 25th Anniversary Denali Package available ...
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...
These Stocks Are Moving the Most Today: Nvidia, Micron, Uber, FuboTV, Inari Medical, Denali Therapeutics, and More
Nvidia stock rises after the artificial-intelligence chip maker unveils its next generation gaming graphic cards, while ...
Travel Weekly18h
Holland America Line is making improvements to its Denali Lodge in Alaska
HAL is planning a $70 million expansion over the next three years, including the construction of a new guestroom building.
Geologists Solve a 620-Mile Mystery: The Forgotten History of the Denali Faults
New research on the Denali Fault reveals three geologic sites were once united in a suture zone, marking the integration of ...
Holland America announces $70M investment to enhance Denali Lodge, Cruisetours
Holland America Line announced a $70M capital investment that will expand guest capacity while elevating the line’s Denali property experience ...
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for ...
Denali Therapeutics’ Phase II/III trial of ALS therapy fails to meet primary endpoint
The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
Fairbanks Daily News-Miner2d
Denali Bancorporation increases dividend to $0.85 per share
Denali Bancorporation, Inc., the parent company of Denali State Bank, announced a $0.05 increase in its quarterly cash ...